Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors

Thrombosis and Haemostasis

Volumn 93, Issue 2, 2005, Pages 212-219

  Kassiri, Zamaneh ^a   Khokha, Rama ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Extracellular matrix; Genetic mouse models; Heart disease; Metalloproteinases; Tissue inhibitor of metalloproteinases

Indexed keywords

CELL SURFACE PROTEIN; COLLAGENASE; DISINTEGRIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; REGULATOR PROTEIN; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

CONGESTIVE CARDIOMYOPATHY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETIC MODEL; HEART DEVELOPMENT; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUE STRUCTURE;

ANIMALS; EXTRACELLULAR MATRIX; HEART; HEART DISEASES; HUMANS; METALLOPROTEASES; MICE; MYOCARDIUM; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 13844253989     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-08-0522     Document Type: Review

References (124)

1. Weber KT, et al. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-92.
2. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 2003; 4: 926-37.
3. Kim CW, et al. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 1994; 5: 797-805.
4. VanWinkle WB, et al. Localization of the transmembrane proteoglycan syndecan-4 and its regulatory kinases in costameres of rat cardiomyocytes: a deconvolution microscopic study Anat Rec 2002; 268: 38-46.
5. Debelle L, Tamburro AM. Elastin: molecular description and function. Int J Biochem Cell Biol 1999; 31: 261-72.
6. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57: 195-202.
7. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Cite Res 2002; 90: 251-62.
8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry Circ Res 2003; 92: 827-39.
9. Burgess ML, et al. Integrin-mediated collagen gel contraction by cardiac fibroblasts. Effects of angiotensin II. Circ Res 1994; 74: 291-8.
10. Carver W, et al. Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol 1995; 165: 425-37.
11. van der Flier A, Kuikman I, Baudoin C, et al. A novel beta 1 integrin isoform produced by alternative splicing: unique expression in cardiac and skeletal muscle. FEBS Lett 1995; 369: 340-4.
12. Zhidkova NI, et al. Novel isoform of beta 1 integrin expressed in skeletal and cardiac muscle. Biochem Biophys Res Common 1995; 214: 279-85.
13. Simpson DG, et al. Regulation of cardiac myocyte protein turnover and myofibrillar structure in vitro by specific directions of stretch. Circ Res 1999; 85: e59-69.
14. Ross RS. The extracellular connections: the role of integrins in myocardial remodeling. J Card Fail 2002; 8(6 Suppl): S326-31.
15. Li S, et al. Fluid shear stress activation of focal adhesion kinase. Linking to mitogen-activated protein kinases. J Biol Chem 1997; 272: 30455-62.
16. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71: 435-78.
17. Pham CG, et al. Striated muscle-specific beta(1D)-integrin and FAK are involved in cardiac myocyte hypertrophic response pathway. Am J Physiol Heart Circ Physiol 2000; 279: H2916-26.
18. Franchini KG, et al. Early activation of the multi-component signaling complex associated with focal adhesion kinase induced by pressure overload in the rat heart. Circ Res 2000; 87: 558-65.
19. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-62.
20. Brilla CG, Rupp H. Myocardial collagen matrix remodeling and congestive heart failure. Cardiologia 1994; 39(12 Suppl 1): 389-93.
21. Gunja-Smith Z, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996; 148: 1639-48.
22. Feldman AM, Li YY, McTiernan CF. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 2001; 357: 654-5.
23. Bonnin CM, Sparrow MP, Taylor RR. Collagen synthesis and content in right ventricular hypertrophy in the dog. Am J Physiol 1981; 241: H708-13.
24. Weber KT, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20: 3-16.
25. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004; 9: 43-51.
26. Li YY, MeTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999; 42: 162-72.
27. Siwik DA, et al. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86: 1259-65.
28. Giroir BP, et al. Inhibition of tumor necrosis factor prevents myocardial dysfunction during burn shock. Am J Physiol 1994; 267: H118-24.
29. Kapadia S, Lee J, Torre-Amione G, et al. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96: 1042-52.
30. Kapadia SR, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997; 81: 187-95.
31. Fine A, Poliks CF, Donahue LP, et al. The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J Biol Chem 1989; 264: 16988-91.
32. Raghow R, Postlethwaite AL, Keski-Oja J, et al. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987; 79: 1285-8.
33. Edwards DR, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. Embo J 1987; 6: 1899-904.
34. Schiemann WP, et al. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem 2002; 277: 27367-77.
35. Hojilla CV, et al. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-21.
36. Folgueras AR, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411-24.
37. Puente XS, Sanchez LM, Overall CM, et al. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4: 544-58.
38. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17: 7-30.
39. Fishman DA, et al. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996; 16: 150-9.
40. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-29.
41. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
42. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998; 98: 1699-702.
43. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271: 9135-40.
44. Holmbeck K, Bianco P, Birkedal-Hansen H. MT1-mmp: a collagenase essential for tumor cell invasive growth. Cancer Cell 2003; 4: 83-4.
45. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol 2004; 286: H1-H10.
46. Steffensen B, et al. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 1995; 270: 11555-66.
47. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
48. Vincenti MP, Coon CI, Mengshol JA, et al. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem J 1998; 331: 341-6.
49. Nuttall RK, et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129-34.
50. Brooks PC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αv β3. Cell 1996; 85: 683-93.
51. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13: 35-48.
52. Chapman RE, et al. Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol 2003; 35: 539-48.
53. Coker ML, et al. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999; 277: H777-87.
54. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-9.
55. Lum L, Reid MS, Blobel CP. Intracellular maturation of the mouse metalloprotease disintegrin MDC15. J Biol Chem 1998; 273: 26236-47.
56. Roghani M, Becherer JD, Moss ML, et al. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 1999; 274: 3531-40.
57. Hougaard S, et al. Trafficking of human ADAM 12-L: retention in the trans-Golgi network. Biochem Biophys Res Commun 2000; 275: 261-7.
58. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281-4.
59. Werb Z, Yan Y. A cellular striptease act. Science 1998; 282: 1279-80.
60. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
61. Reddy P, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000; 275: 14608-14.
62. Perrella MA, et al. Regulation of heparin-binding epidermal growth factor-like growth factor mRNA levels by hypertrophic stimuli in neonatal and adult rat cardiac myocytes. J Biol Chem 1994; 269: 27045-50.
63. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-35.
64. Latchman DS. Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent. Int J Exp Pathol 1999; 80: 189-96.
65. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40.
66. Yan Y, Shirakabe K, Werb Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 2002; 158: 221-6.
67. Lee DC, et al. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann N Y Acad Sci 2003; 995: 22-38.
68. Killar L, White J, Black R, et al. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999; 878: 442-52.
69. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-79.
70. Sottrup-Jensen L, Birkedal-Hansen H. Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 1989; 264: 393-401.
71. Mott JD, Thomas CL, Rosenbach MT, et al. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J Biol Chem 2000; 275: 1384-90.
72. Petitclerc E, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000; 275: 8051-61.
73. Herman MP, Sukhova GK, Kisiel W et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107: 1117-26.
74. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
75. Langton KP, et al. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation. J Biol Chem 1998; 273: 16778-81.
76. Yu WH, Ya S, Meng Q, et al. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275: 31226-32.
77. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510.
78. Liu YE, et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997; 272: 20479-83.
79. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-27.
80. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39-44.
81. Kashiwagi M, et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276: 12501-4.
82. Amour A, Knight CG, Webster A, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473: 275-9.
83. Tortorella MD, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999; 284: 1664-6.
84. Young DA, Phillips BW, Lundy C, et al. Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochem J 2002; 364: 89-99.
85. Leco KJ, Apte SS, Taniguchi GT, et al. Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997; 401: 213-7.
86. Li YY, Fet al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98: 1728-34.
87. Tyagi SC, et al. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 1996; 63: 185-98.
88. Altieri P, Brunelli C, Garibaldi S, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648-56.
89. Thomas CV, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-15.
90. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-9.
91. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-30.
92. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-20.
93. Yokoseki O, Yazaki Y, Suzuki J, et al. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy. Jpn Circ J 2000; 64: 352-7.
94. Noji Y, Shimizu M, Ino H, et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004; 68: 355-60.
95. Barton PJ, Birks EJ, Felkin LE, et al. Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. J Heart Lung Transplant 2003; 22: 738-44.
96. Wang X, Yang L, Qi F, et al. Myocardial matrix metalloproteinase-3 and matrix metalloproteinase inhibitor-1 expression in congestive heart failure. Zhonghua Nei Ke Za Zhi 2002; 41: 453-5.
97. Timms PM, et al. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002; 15: 269-72.
98. Lindsay MM, et al. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136-41.
99. Wilson EM, et al. Plasma matrix metalloproteinase and inhibitor profiles inpatients with heart failure. J Card Fail 2002; 8: 390-8.
100. Yamazaki T, Lee JD, Shimizu H, et al. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004; 6: 41-5.
101. Roten L, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000; 32: 109-20.
102. Creemers EE, Davis JN, Parkhurst AM, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003; 284: H364-71.
103. Caterina J, et al. Murine TIMP-2 gene-targeted mutation. Ann N Y Acad Sci 1999; 878: 528-30.
104. Fedak PW, et al. TIMP-3 Deficiency leads to dilated cardiomyopathy. Circulation 2004; 110: 2401-9.
105. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001; 108: 817-29.
106. Fata JE, Leco KJ, Voura EB, et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 2001; 108: 831-41.
107. Kim HE, Dalal SS, Young E, et al. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000; 106: 857-66.
108. Hayashidani S, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285: H1229-35.
109. Ducharme A, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
110. Romanic AM, Harrison SM, Bao W et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002; 54: 549-58.
111. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000; 97: 4052-7.
112. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99: 81-92.
113. Weskamp G, Cai H, Brodie TA, et al. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol Cell Biol 2002; 22: 1537-44.
114. Kurisaki T, Masuda A, Sudo K, et al. Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis. Mol Cell Biol 2003; 23: 55-61.
115. Iwamoto R, Yamazaki S, Asakura M, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A 2003; 100: 3221-6.
116. Shi W, Chen H, Sun J, et al. TACE is required for fetal murine cardiac development and modeling. Dev Biol 2003; 261: 371-80.
117. Zhao J, et al. Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol 2001; 232: 204-18.
118. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943-52.
119. Mann GB, et al. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993; 73: 249-61.
120. Luetteke NC, Qiu TH, Peiffer RL, et al. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993; 73: 263-78.
121. Chen B, Bronson RT, Klaman LD, et al, Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000; 24: 296-9.
122. Ozeelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99: 8880-5.
123. Zhou HM, Weskamp G, Chesneau V et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol 2004; 24: 96-104.
124. Kurohara K, Komatsu K, Kurisaki T, et al. Essential roles of Meltrin beta (ADAM19) in heart development. Dev Biol 2004; 267: 14-28.